Total Voting Rights and Directors' Shareholdings

RNS Number : 1304K

Advanced Oncotherapy PLC

27 August 2019

 

27 August 2019

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company") 

Total Voting Rights and Directors' Shareholdings

Advanced Oncotherapy (AIM: AVO), the developer of a next generation proton therapy system for cancer treatment confirms that, following Second Admission on 19 August 2019 as described in the Company's announcement of 7 August 2019, the Company's issued share capital consists of 230,226,094 Ordinary Shares with one voting right each.

The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of Ordinary Shares in the Company with voting rights is 230,226,094. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

Directors' Shareholdings

Set out below are details of the Directors' interests in Ordinary Shares following Second Admission.

Director	Number of Ordinary Shares	% of current issued share capital
Mr. Chunlin Han, Mrs. RenHua Zhang and Dr Yuelong Huang*	45,000,000	19.55
Mr Michael Bradfield	7,193,240	3.12
Michael Sinclair & Family	7,469,660	3.24
Mr Gabriel Urwitz**	6,551,289	2.85
Dr P N Plowman	4,042,804	1.76
Dr Enrico C Vanni	2,126,361	0.92
Mr Nicolas Serandour	1,760,467	0.76
Mr Steve Myers	783,902	0.34
Mr Hans Van Celsing	142,500	0.06

*Liquid Harmony Ltd holds 45,000,000 Ordinary Shares and is represented by Mr. Chunlin Han, Mrs. RenHua Zhang and Dr Yuelong Huang, all Non-Executive Directors.

**Gabriel Urwitz, Non-Executive Director, holds 62,500 Ordinary Shares in his own name. In addition, AB Segulah, of which Mr Urwitz is a director and shareholder, holds 6,488,789 Ordinary Shares. As a result, AB Segulah and Mr Urwitz in aggregate have a total interest of 6,551,289 Ordinary Shares, equivalent to 2.85 per cent. of the Company's current issued share capital.

Defined terms used in this announcement shall have the same meaning as in the announcement of 7 August 2019 unless otherwise defined herein. 

Advanced Oncotherapy Plc	www.avoplc.com
Dr. Michael Sinclair, Executive Chairman	Tel: [phone]
Nicolas Serandour, CEO
Allenby Capital Limited (Nominated Adviser & Joint Broker)
Nick Athanas / Liz Kirchner / Nicholas Chambers		Tel: [phone]
Stifel Nicolaus Europe (Joint Broker)
Jonathan Senior	Tel: [phone]
Walbrook PR (Financial PR & IR)	Tel: [phone] or [e-mail]
Paul McManus / Anna Dunphy	Mob: [phone] / Mob: [phone]

About Advanced Oncotherapy Plc www.avoplc.com

Advanced Oncotherapy is a provider of particle therapy in the treatment of cancer, which harnesses the very best in modern technology. Advanced Oncotherapy's R&D team, ADAM, in Geneva, focuses on the development of a proprietary proton accelerator - LIGHT (Linac Image Guided Hadron Technology). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a compact and truly modular unit, offering significant cost advantages. LIGHT also delivers proton beams in a way that facilitates greater precision and electronic control, which are not achievable with currently available alternative technologies.

Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology, offering better health outcomes and lower treatment related side effects.

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton or particle therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of cutting edge, cost-effective systems for particle therapy.

 

END

 

 

MSCPGURPRUPBGQW